在基础上建立:基于Venetoclax的组合治疗急性髓性白血病
Emmanuella Oyogoa1, Elie Traer2,3, Jeffrey Tyner2,3
1Department of Internal Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Cancers
|July 29, 2023
概括
新的venetoclax (VEN) 组合正在研究以克服耐药性并改善老年急性髓性白血病 (AML) 患者的治疗结果,超越标准的低甲基化剂 (HMA) + VEN治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 前线急性髓性白血病 (AML) 治疗选择取决于患者的健康状况和遗传因素.
- 老年,不适合的AML患者通常接受venetoclax (VEN) 加上低甲基化剂 (HMA).
- 针对特定的AML基因组子组正在出现向疗法,允许个性化治疗.
研究的目的:
- 审查正在进行的临床试验,调查AML的新型VEN组合.
- 探索克服VEN抵抗机制的策略.
- 为了改善老年AML患者的治疗结果,超出目前的HMA + VEN标准.
主要方法:
- 对AML治疗当前临床试验的审查.
- 分析新兴的向疗法和药物组合.
- 专注于解决VEN耐药性的策略.
主要成果:
- 目前正在调查几种包含VEN的新型药物组合.
- 这些包括IDH1/2抑制剂,FLT3抑制剂,抗CD47抗体,MDM2抑制剂和p53再激活剂.
- 这些组合旨在提高疗效,克服耐药性途径.
结论:
- 基于VEN的新型组合显示出改善AML治疗的希望.
- 向治疗为个性化AML治疗策略提供了新的途径.
- 进一步的研究至关重要,以确定这些组合在老年AML患者的疗效.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
338
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
338

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
